Stephen Ashe, MD
Family Medicine · Richmond, VANPI 1952300634
Payments from drug & device makers
Across 337 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$697
- Novo Nordisk$631
- AstraZeneca$588
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$471
- Amarin Pharma, Inc.$452
- Lilly USA, LLC$421
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,107100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $697 |
| Novo Nordisk | 39 | $631 |
| AstraZeneca | 39 | $588 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $471 |
| Amarin Pharma, Inc. | 30 | $452 |
| Lilly USA, LLC | 27 | $421 |
| GSK | 28 | $338 |
| Pfizer | 15 | $254 |
| Boehringer Ingelheim | 13 | $225 |
| Amgen | 5 | $97 |
| Genentech USA, Inc. | 6 | $81 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $68 |
| Eisai Inc. | 4 | $66 |
| Bayer | 4 | $60 |
| Nestle Healthcare Nutrition Inc. | 4 | $60 |
| Sanofi-aventis U.S. LLC | 4 | $56 |
| Abbott | 3 | $54 |
| Sanofi Pasteur Inc. | 3 | $44 |
| Dexcom, Inc. | 2 | $40 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Exact Sciences | 2 | $37 |
| Impulse Dynamics (USA) Inc. | 1 | $37 |
| Johnson & Johnson(2 entities) | 2 | $34 |
| Novartis | 2 | $31 |
| Vivus LLC | 2 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Mannkind Corporation | 1 | $20 |
| Edwards Lifesciences | 1 | $18 |
| Bioventus LLC | 1 | $16 |
| Abiomed | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Insulet Corporation | 1 | $15 |
| Cequr Corporation | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$5,107 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 79 | $77,541 |
| OzempicSemaglutide | 27 | $27,685 |
| XareltoRivaroxaban | 34 | $25,241 |
| EliquisApixaban | 33 | $21,439 |
| JardianceEmpagliflozin | 16 | $19,361 |
| TrulicityDulaglutide | 11 | $12,779 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $12,405 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,611 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 19 | $5,488 |
| LexaproEscitalopram Oxalate | 11 | $5,349 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $4,944 |
| Atorvastatin Calcium | 441 | $3,172 |
| Amlodipine Besylate | 440 | $1,810 |
| Levothyroxine Sodium | 194 | $1,740 |
| Diclofenac Sodium | 92 | $1,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $588 | $77,54179 claims |
| Novo NordiskOzempic | $631 | $27,68527 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $225 | $25,97228 claims |
| Johnson & JohnsonXarelto | $34 | $25,24134 claims |
| PfizerEliquis | $254 | $21,43933 claims |
| Lilly USA, LLCTrulicity | $421 | $12,77911 claims |
| AbbVieLexapro | $697 | $5,34911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Richmond
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Banks TurnerRichmond$74K
- James FosterRichmond$27K
- George MaughanRichmond$21K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.